Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
118.97
-0.50 (-0.42%)
At close: Dec 20, 2024, 4:00 PM
119.30
+0.33 (0.28%)
After-hours: Dec 20, 2024, 5:02 PM EST
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,314 employees as of December 31, 2023. The number of employees increased by 152 or 13.08% compared to the previous year.
Employees
1,314
Change (1Y)
152
Growth (1Y)
13.08%
Revenue / Employee
$1,248,362
Profits / Employee
$92,728
Market Cap
11.36B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,314 | 152 | 13.08% |
Dec 31, 2022 | 1,162 | 322 | 38.33% |
Dec 31, 2021 | 840 | -26 | -3.00% |
Dec 31, 2020 | 866 | 123 | 16.55% |
Dec 31, 2019 | 743 | 244 | 48.90% |
Dec 31, 2018 | 499 | 244 | 95.69% |
Dec 31, 2017 | 255 | 58 | 29.44% |
Dec 31, 2016 | 197 | -73 | -27.04% |
Dec 31, 2015 | 270 | 66 | 32.35% |
Dec 31, 2014 | 204 | 58 | 39.73% |
Dec 31, 2013 | 146 | 43 | 41.75% |
Dec 31, 2012 | 103 | 5 | 5.10% |
Dec 31, 2011 | 98 | 0 | - |
Dec 31, 2010 | 98 | 35 | 55.56% |
Dec 31, 2009 | 63 | -20 | -24.10% |
Dec 31, 2008 | 83 | -42 | -33.60% |
Dec 31, 2007 | 125 | 8 | 6.84% |
Dec 31, 2006 | 117 | -6 | -4.88% |
Dec 31, 2005 | 123 | 11 | 9.82% |
Dec 31, 2004 | 112 | 6 | 5.66% |
Dec 31, 2003 | 106 | 17 | 19.10% |
Dec 31, 2002 | 89 | 4 | 4.71% |
Dec 31, 2001 | 85 | 14 | 19.72% |
Dec 31, 2000 | 71 | 15 | 26.79% |
Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Tenet Healthcare | 106,500 |
Universal Health Services | 96,700 |
DaVita | 70,000 |
Solventum | 20,098 |
Smith & Nephew | 19,081 |
AptarGroup | 13,800 |
Globus Medical | 5,000 |
BioMarin Pharmaceutical | 3,401 |
SRPT News
- 1 day ago - Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku - Reuters
- 3 days ago - Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 - Business Wire
- 22 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 25 days ago - Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs - Business Wire
- 6 weeks ago - Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step - Seeking Alpha
- 6 weeks ago - Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments - Business Wire
- 2 months ago - Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results - Business Wire